title: Association of genetic variations in GNB1 with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan.
abstract: BACKGROUND
  The aim of this study was to evaluate whether polymorphisms in the guanine nucleotide binding (G protein), beta polypeptide 1 (GNB1) gene are associated with a rapid virological response (RVR) among HCV genotype 1 (HCV-1) and 2 (HCV-2) infected patients receiving peginterferon plus ribavirin treatment (PEG-IFNα-RBV).
  
  
  METHODS
  We analyzed the association between RVR to PEG-IFNα-RBV therapy and 4 tagging single nucleotide polymorphisms (SNPs) of the GNB1 gene. This study included 265 HCV-1 and 195 HCV-2 infected patients in a Chinese population in Taiwan.
  
  
  RESULTS
  Among the GNB1 SNPs examined, the combination of genotypes G/G and G/T populations of rs12126768 was significant inversely correlated with RVR in HCV-1 infected patients (P = 0.0330), whereas HCV-2 infected patients, combination of A/A and A/C genotypes populations at rs4648727 responded better to the PEG-IFNα-RBV treatment (P = 0.0089). However, there were no significant differences in the allele frequencies of those SNPs between RVR responders and non-responders. Several RVR susceptibility GNB1 haplotypes were identified, and the ACAT haplotype of the 4 SNPs may increase the successful outcomes of HCV-1 and HCV-2 infected patients (P = 0.0261 and P = 0.0253, respectively).
  
  
  CONCLUSIONS
  The data for GNB1 SNPs and the association of RVR showed that GNB1 polymorphisms might be associated with the therapeutic outcomes of HCV-1 and HCV-2 infected patients under standard of care (SOC) treatment.
authors.affiliation: Department of Pharmacy, College of Pharmacy, China Medical University, Taichung 40402, Taiwan.
authors.forename: Yun-Ping
authors.initials: YP
authors.lastname: Lim
authors.forename: Fuu-Jen
authors.initials: FJ
authors.lastname: Tsai
authors.forename: Wen-Ling
authors.initials: WL
authors.lastname: Liao
authors.forename: Ni
authors.initials: N
authors.lastname: Tien
authors.forename: Dong-Zong
authors.initials: DZ
authors.lastname: Hung
authors.forename: Cheng-Yuan
authors.initials: CY
authors.lastname: Peng
authors.forename: Lei
authors.initials: L
authors.lastname: Wan
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D044466:Asian People / Q000235:genetics*; D016009:Chi-Square Distribution; D016001:Confidence Intervals; D004359:Drug Therapy, Combination; D005260:Female; D044387:GTP-Binding Protein beta Subunits / Q000235:genetics*; D005787:Gene Frequency; D006239:Haplotypes; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011092:Polyethylene Glycols / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D013624:Taiwan; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; C516790:GNB1 protein, human; D044387:GTP-Binding Protein beta Subunits; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a